Status:
COMPLETED
Precise Gene Signature for Predicting Outcomes in PDAC
Lead Sponsor:
The Fourth Affiliated Hospital of Anhui Medical University
Conditions:
Stage I-II Pancreatic Ductal Adenocarcinoma (PDAC)
Precise Prognostic and Predictive Signature
Eligibility:
All Genders
18+ years
Brief Summary
The current TNM staging system is not sufficient for prediction of prognosis and cannot precisely identify the patients who are in greater need of adjuvant therapy in pancreatic ductal adenocarcinoma ...
Eligibility Criteria
Inclusion
- Availability of hematoxylin and eosin slides with invasive tumor components
- Availability of clinicopathologic characteristics and follow-up data
- No previous history of cancer
Exclusion
- No formalin-fixed, paraffin-embedded (FFPE) tumor sample of primary tumor
- Receipt of any neoadjuvant and/or adjuvant cancer-directed therapy
- Survival time \<3 months after resection
Key Trial Info
Start Date :
April 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 22 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05441189
Start Date
April 19 2021
End Date
June 22 2022
Last Update
July 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025